REVIEW PAPER
Combined bacterial and viral treatment: a novel anticancer strategy
Submission date: 2015-04-28
Final revision date: 2015-05-11
Acceptance date: 2015-05-13
Publication date: 2015-10-15
Cent Eur J Immunol 2015;40(3):366-372
KEYWORDS
ABSTRACT
An idea for a new combination therapy will be described herein. It is a proposition to combine viral and bacterial anticancer therapies and make them fight cancer in concert. We analyzed biological anticancer therapies and found overlapping advantages and disadvantages which led us to the conclusion that the combination therapy has the potential to create a new therapeutic quality. It is surprising how many weaknesses of viral anticancer therapy are the strengths of bacterial anticancer therapies and the other way round. We review the facts behind this concept and try to assess its value. We propose a few strategies how to combine these two therapies but as far as the review can go, final answers will have to come from the experiments. This review is the first attempt to describe a new strategy and understand the means for this idea but also to raise new questions and discuss new ways to look at anti-cancer treatment.
REFERENCES (59)
1.
Tsung K, Norton JA (2006): Lessons from Coley’s Toxin. Surg Oncol 15: 25-28. Available from: http://www.ncbi.nlm.nih.gov/pu... (Accessed 11 January 2015).
2.
Kelly E, Russell SJ (2007): History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15: 651-659. Available from: http://www.ncbi.nlm.nih.gov/pu....
3.
Dock G (1904): The influence of complicating diseases upon leukćmia. Am J Med Sci 127: 563-592.
4.
Rodriguez R, Schuur ER, Lim HY, et al. (1997): Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 57: 2559-2563.
5.
Barker DD, Berk AJ (1987): Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156: 107-121.
6.
Fueyo J, Gomez-Manzano C, Alemany R, et al. (2000): A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19: 2-12.
7.
Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991): p53 mutations in human cancers. Science 253: 49-53.
8.
Graeber TG, Osmanian C, Jacks T, et al. (1996): Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91.
9.
Yu JL, Rak JW, Coomber BL, et al. (2002): Effect of p53 status on tumor response to antiangiogenic therapy. Science 295: 1526-1528.
11.
Kawai K, Miyazaki J, Joraku A (2013): Bacillus Calmette- Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci 104: 22-27.
12.
Brandau S, Riemensberger J, Jacobsen M, et al. (2001): NK cells are essential for effective BCG immunotherapy. Int J Cancer 92: 697-702.
13.
Ratliff TL, Gillen D, Catalona WJ (1987): Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 137: 155-158.
14.
Shelley MD, Kynaston H, Court J, et al. (2001): A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88: 209-216.
15.
Dang LH, Bettegowda C, Huso DL, et al. (2001): Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A 98: 15155-15160.
16.
Kasinskas RW, Forbes NS (2006): Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol Bioeng 94: 710-721.
17.
Wood LM, Paterson Y (2014): Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front Cell Infect Microbiol 4: 51.
18.
Pesonen S, Kangasniemi L, Hemminki A (2011): Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 8: 12-28.
19.
Shayakhmetov DM, Li ZY, Ni S, Lieber A (2004): Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 78: 5368-5381.
20.
Tao N, Gao GP, Parr M, et al. (2001): Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 3: 28-35.
21.
Vetrini F, Ng P (2011): Liver-directed gene therapy with helper-dependent adenoviral vectors: current state of the art and future challenges. Curr Pharm Des 17: 2488-2499.
22.
Alemany R, Suzuki K, Curiel DT (2000): Blood clearance rates of adenovirus type 5 in mice. J Gen Virol: 2605-2609.
23.
Reid T, Galanis E, Abbruzzese J, et al. (2002): Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520) phase ii viral, immunologic, and clinical endpoints. Cancer Res 33: 6070-6079.
24.
Clairmont C, Lee KC, Pike J, et al. (2000): Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 181: 1996-2002.
25.
Toso JF, Gill VJ, Hwu P, et al. (2002): Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20: 142-152.
26.
Ganai S, Arenas RB, Sauer JP, et al. (2011): In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis. Cancer Gene Ther 18: 457-466.
27.
Kasinskas RW, Forbes NS (2007): Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res 67: 3201-3209.
28.
Ireton K, Rigano LA, Polle L, Schubert WD (2014): Molecular mechanism of protrusion formation during cell-to-cell spread of Listeria. Front Cell Infect Microbiol 4: 21.
29.
Patyar S, Joshi R, Byrav DS, et al. (2010): Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci 17: 21.
30.
Haag A, Menten P, Van Damme J, et al. (2000): Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Human Gene Ther 11: 597-609.
31.
Yoon SS, Nakamura H, Carroll NM, et al. (2000): An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 14: 301-311.
32.
Coffey MC, Strong JE, Forsyth PA, Lee PW (1998): Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334.
33.
Yan C, Higgins PJ (2013): Drugging the undruggable: Transcription therapy for cancer. Biochim Biophys Acta 1835: 76-85.
34.
Stein SC, Falck-Pedersen E (2012): Sensing adenovirus infection: activation of interferon regulatory factor 3 in RAW 264.7 cells. J Virol 86: 4527-4537.
35.
Blankenstein T, Coulie PG, Gilboa E, Jaffee EM (2012): The determinants of tumour immunogenicity. Nat Rev Cancer 12: 307-313.
36.
Almendro V, Cheng YK, Randles A, et al. (2014): Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep 6: 514-527.
37.
Nowell PC (1976): The clonal evolution of tumor cell populations. Science 194: 23-28.
38.
Schafer R, Portnoy DA, Brassell SA, Paterson Y (1992): Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. J Immunol 149: 53-59.
39.
Sparer TE, Wynn SG, Clark DJ, et al. (1997): Generation of cytotoxic T lymphocytes against immunorecessive epitopes after multiple immunizations with adenovirus vectors is dependent on haplotype. J Virol 71: 2277-2284.
40.
Alemany R (2012): Design of improved oncolytic adenoviruses. 1st ed. Elsevier Inc. (online). Available from: http://www.ncbi.nlm.nih.gov/pu... (Accessed 11 January 2015).
41.
Sing A, Merlin T, Knopf HP, et al. (2000): Bacterial induction of beta interferon in mice is a function of the lipopolysaccharide component. Infect Immun 68: 1600-1607.
42.
Auerbuch V, Brockstedt DG, Meyer-Morse N, et al. (2004): Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J Exp Med 200: 527-533.
43.
O’Connell RM, Saha SK, Vaidya SA, et al. (2004): Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med 200: 437-445.
44.
Robinson N, McComb S, Mulligan R, et al. (2012): Type I interferon induces necroptosis in macrophages during infection with Salmonella enterica serovar Typhimurium. Nat Immunol 13: 954-962.
45.
Fink SL, Cookson BT (2007): Pyroptosis and host cell death responses during Salmonella infection. Cell Microbiol 9: 2562-2570.
46.
Goldszmid RS, Dzutsev A, Trinchieri G (2014): Host immune response to infection and cancer: unexpected commonalities. Cell Host Microbe 15: 295-305.
47.
Agrawal N, Bettegowda C, Cheong I, et al. (2004): Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A 101: 15172-15177.
48.
Malmgren RA, Flanigan CC (1955): Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res 15: 473-478.
49.
Forbes NS (2010): Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 10: 785-794.
51.
Maciag PC, Radulovic S, Rothman J (2009): The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 27: 3975-3983.
52.
Wigand R, Kümel G (1977): The kinetics of adenovirus infection and spread in cell cultures infected with low multiplicity. Arch Virol 54: 177-187.
53.
Cronin M, Le Boeuf F, Murphy C, et al. (2014): Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy. Mol Ther 22: 1188-1197.
54.
Jamieson AM, Pasman L, Yu S, et al. (2013): Role of tissue protection in lethal respiratory viral-bacterial coinfection. Science 340: 1230-1234.
55.
Nichol KP, Cherry JD (1967): Bacterial-viral interrelations in respiratory infections of children. N Engl J Med 277: 667-672.
56.
Smith AM, Adler FR, Ribeiro RM, et al. (2013): Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog 9: e1003238.
58.
Paterson Y, Guirnalda PD, Wood LM (2010): Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy. Semin Immunol 22: 183-189.
59.
Choi JW, Lee JS, Kim SW, Yun CO (2012): Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev 64: 720-729.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
